We are a biotechnology company focused on the discovery and development of
lipidomic-based therapeutic antibodies, an emerging field of medical science
that targets bioactive signaling lipids to treat a wide range of human diseases.
We have two product candidates that are currently in clinical development, and
one that is currently awaiting FDA clearance to initiate a Phase 1 clinical
iSONEP(TM) is the ocular formulation of sonepcizumab, a humanized monoclonal
antibody ("mAb") against sphingosine-1-phosphate ("S1P"). Sphingomab(TM) is the
original mouse version of this monoclonal antibody. iSONEP is administered by
intravitreal (inside the eye) injection, and has demonstrated multiple
mechanisms of action in ocular models of disease, including anti-angiogenesis,
anti-inflammatory, anti-fibrotic and anti-vascular permeability.